The global cancer biomarkers market size is expected to reach around US$ 29.8 Bn by 2026 and will grow at noteworthy CAGR of around 11.9% over the forecast period 2019 to 2026.
Cancer biomarker is a substance that helps to indicate the presence of cancer in the body. This substance may be a molecule secreted by a tumor or specific response of the body to a tumor. Genetic, proteomic, and glycomic biomarkers used for various applications such as diagnosis, epidemiology, and prognosis. These are also used in cancer research or drug discovery process field. Biomarkers can be identified in blood, urine, stool, tissue, and other body fluids. Currently, various biomarkers are using for patient care such as BRCA1/BRCA2 (Breast /Ovarian cancer), EGFR (Non-small cell lung carcinoma), HER-2 (Breast cancer), PSA (Prostate cancer), S100 (Melanoma), and AFP (liver cancer). Based on the specific recognition of intracellular and cancerous cell surface biomarkers, various technologies have been developed to identify a tumor in the body. These technologies include immunoassays, cytogenetic testing, omics technology, and imaging technologies such as CT, Ultrasound, MRI, PET, and mammography.
Increasing healthcare expenditure, technological advancements which led to high speed and more accuracy, favorable reimbursements in developed countries, and growing awareness about regular health checkups are the major driving factors of the cancer biomarkers market. Additionally, rising number of cancer patients across the world, investment by market players for the development and commercialization of cancer biomarkers, presence of strong pipeline, and increasing affordability of patients for advanced cancer treatment are some of the other factors that propel the market. For instance, according to the World Health Organization (WHO), global burden of cancer reached to 18.1 million new cases and 9.6 million deaths in 2018. Increased in cancer cases were observed due to several factors such as ageing, unhealthy lifestyle, and changing social & economic scenario. High capital investment for research, development, and commercialization, stringent & complex regulatory requirements, and low or no reimbursement in low and middle income countries are key restraining factors of the market. Furthermore, specimen collection and storage, detailed tracking, and retrieval software are necessary for proper management and accurate result. These issues are also anticipated to hinder the overall cancer biomarkers market growth.
Based on type, the cancer biomarkers market has been segmented into protein biomarker, genetic biomarker, and others. Other segment includes viral, cell, and carbohydrate biomarkers. Protein biomarkers accounted for the largest segment in the market in 2018 due to its ability of early diagnosis and presence of several commercial biomarkers.
On the basis of technology used for profiling, the market has been categorized into omics technology, immunoassay, imaging technologies, and cytogenetic testing. The omics technology segment accounted for the largest share of the market in 2018. This can be attributed to revolution in the omics technologies since last decade responsible for the increase in the applications of biomarkers.
Based on the application, prognostics segment held the maximum share of the market in 2018 and is expected to maintain to maintain its dominance during the forecasts period. However, the diagnosis segment is anticipated to witness the fastest growth in coming years.
Based on the cancer type, breast cancer accounted for the largest share of the market due to more awareness about screening, availability of commercialized products, and high sensitivity of markers to detect breast cancer. Lung cancer, colorectal cancer, prostate cancer, leukemia, thyroid gland cancer, kidney cancer, and bladder cancer are some of the other cancers where biomarkers are used for the various applications.
North America dominated the cancer biomarkers market in 2018 due to high ongoing research in the development of cancer biomarkers, mergers & collaborations for the development and commercialization of products, favorable reimbursement for cancer diagnosis & treatment, and awareness about companion diagnostics and personalized medicines. For instance, in January 2017, GeneNews launched a blood-based biomarker test, BreastSentry, for risk assessment of breast cancer in the U.S.
The market research study on “Cancer Biomarkers Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global cancer biomarkers market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global cancer biomarkers market, its type, technology, cancer type, application, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global cancer biomarkers market size, and segment markets by type, technology, cancer type, application, and geography along with the information on companies operating in the market. The cancer biomarkers market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments has been covered under the scope of the report.
The players profiled in the report include Abbott Laboratories, Agilent Technologies, Becton Dickinson and Company, Hologic, Illumina, Merck & Co., Qiagen N.V., Roche Diagnostics, and Thermo Fisher Scientific. The competitors are involved in the research and development activities, commercialization of sensitive products, and collaborations for the development & commercialization to enhance their market footprints.
By Cancer Type